We are pleased to announce that TOPADUR Pharma in collaboration with the University Hospital of Zurich and the University of Zurich has received CHF 859k funding by Innosuisse. We are happy to work together with Prof. Scharl and Prof. Pruschy and their teams to develop an innovative drug for the prevention and treatment of colorectal cancer. The project entitled “Translational IND enabling studies to develop an innovative drug candidate, TOP-V122 for the treatment and prevention of colorectal cancer” will bring together a powerful and effective small molecule drug discovery & development from the biotech start-up company TOPADUR Pharma together with world leader academic experts in CRC. It is intended to better understand the tumor response at the ex-vivo and in-vivo levels of our novel pharmacological agent alone or in combination with classical chemotherapy and /or ionizing radiation. A major goal is to understand treatment mechanisms and to translate these novel combined treatment modalities into a clinical environment. We believe that this drug candidate has a huge potential to treat and prevent such a devastating disease like colorectal cancer resulting in improved patients care.
TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.Read more
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.Read more
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.Read more